Recently conducted observational trials in Israel and the United Kingdom have documented improved symptoms following the use of cannabis products among patients with post-traumatic stress. These outcomes include statistically significant changes in sleep quality and in anxiety, fewer nightmares, and improved quality of life.
“These findings contribute robust evidence for clinicians regarding the potential benefits of medical cannabis in reducing the opioid burden for patients receiving long-term opioid therapy and possibly reduc[ing] their risk for overdose.”
By taking cannabis products off street corners and placing them behind the counter, lawmakers can provide consumers with a safer experience and greatly reduce their risk of being inadvertently exposed to contaminated products.
Investigators reported, “Contrary to concerns about spillover effects, implementation of legalized non-medical cannabis coincided with decreases in alcohol and cigarette use and pain reliever misuse.”
Sixty-one percent of respondents said that they “replaced” prescription opioids and/or benzodiazepines with medical cannabis – a finding that is consistent with several other studies.
“[T]he implementation of medical marijuana laws (MMLs) and recreational marijuana laws (RMLs) reduced morphine milligram equivalents per enrollee by seven percent and 13 percent, respectively.”
“We found that the legalization of recreational marijuana use in Colorado and Washington did not result in an increase in SUD [substance use disorder] treatment admissions for cocaine, opioids, or methamphetamines among adolescents or emerging adults.”
“Increased medical and recreational storefront dispensary counts are associated with reduced opioid related mortality rates during the study period. These associations appear particularly strong for deaths related to synthetic opioids such as fentanyl.”